US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson’s Disease and Restless Leg Syndrome

Huntsville, AL, March 25th, 2013

Serina Therapeutics, Inc., a pharmaceutical research and development company developing a proprietary polymer technology for drug delivery, announced today that the company has been awarded another key patent from the United States Patent and Trademark Office. The patent entitled “Subcutaneous delivery of poly(oxazoline) conjugates” - US Patent Number 8,383,093 B1 dated February 26th, 2013 covers the synthesis and composition of polyoxazoline (POZ) polymers for the treatment of dopamine-responsive disorders.

“The awarding of this patent represents another major milestone in the development of our polymer technology”, said Dr. Randall Moreadith, President and Chief Executive Officer. “We have entered into IND-enabling studies to advance SER-214 into humans in early 2014. This is a key patent as it covers both composition of matter and use of POZ conjugates for the treatment of dopamine-responsive disorders. These include Parkinson’s disease and restless leg syndrome – which remain significant unmet medical needs”.

SER-214, a POZ conjugate of the potent dopamine agonist rotigotine, was designed to deliver continuous dopaminergic stimulation (CDS) from a single, weekly subcutaneous administration via a standard insulin syringe. CDS has been a long-sought clinical strategy in patients with both Parkinson’s disease and restless leg syndrome.

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing numerous unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com